Navigation Links
Sihuan's First-to-market Generic Drug Roxatidine Receives New Drug Certificate and Approval for Production
Date:10/31/2012

HONG KONG, Oct. 31, 2012 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) ("Sihuan Pharmaceutical" or the "Company"), a leading pharmaceutical company with the largest cardio-cerebral vascular ("CCV") drug franchise in China's prescription market, is pleased to announce that Roxatidine Acetate Hydrochloride for Injection ("Roxatidine"), Sihuan Pharmaceutical's first-to-market generic drug, received a new drug certificate and approval for production. The Company plans to launch the drug to the market in or before the first quarter of next year.

Sihuan Pharmaceutical is the first pharmaceutical company to successfully register and develop Roxatidine in China, and has four years of administrative protection for the drug. Roxatidine is a fourth generation H2 receptor antagonist. The drug is categorized into two formulations - oral and injectable. The oral form of the drug was first launched in Japan in 1986 and is mainly used for gastric and duodenal ulcers, zollinger-ellison syndrome, reflux esophagitis and gastritis. The injectable form of the drug, which debuted in Japan in 1995, is mainly used for gastrointestinal ulcers and bleeding and pre-anesthesia application. It is one of the few drugs prescribed in hospitals to treat inpatients suffering from gastrointestinal bleeding. Currently, Roxatidine is widely used in various countries, including Korea, Germany, Italy, the Netherlands, Greece and South Africa.  

Dr. Che Fengsheng, Chairman and CEO of Sihuan Pharmaceutical, said, "Roxatidine has a high clinical value. Based on the hospital retail price, the market size of the same type of drug has already reached RMB$1 billion. Leveraging our strong marketing capabilities and nationwide sales and distribution network, we believe that the official launch and manufacturing of Roxatidine will not only optimize our product mix, but will also strengthen our competitiveness and help us develop the market for t
'/>"/>

SOURCE Sihuan Pharmaceutical Holdings Group Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sihuans First-to-market Generic Drug Roxatidine Passes On-site Inspection for Drug Registration Conducted by the Chinese State Food and Drug Administration
2. Mylan Launches Generic Version of Zyprexa® Tablets
3. Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc.
4. Mylan Launches Generic Lipitor® in Five European Countries
5. Mylan Launches Generic Version of Plavix® Tablets
6. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
7. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
8. Mylan Launches Generic Version of Viramune® Tablets
9. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
10. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
11. Mylan Launches Generic Version of Lipitor®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- Echo Therapeutics, Inc. (NASDAQ: ECTE ... permeation, continuous glucose monitoring and associated technologies, today ... been appointed Chief Executive Officer effective December 22, ... of experience in the medical device, pharmaceutical and ... Vice President, Business Development, Otsuka Pharmaceuticals as well as ...
(Date:12/24/2014)... MASON, Ohio , Dec. 23, 2014 /PRNewswire/ ... industry-leading treatment decision support to healthcare providers for ... that it has secured $30 million in equity ... Virginia C. Drosos , President and Chief ... increased clinical adoption and development of Assurex Health,s ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 /PRNewswire/ ... (NASDAQ: ENDP ) (TSX: ENL), and BioDelivery ... today that they have submitted a New Drug Application ... Food and Drug Administration (FDA).  Buprenorphine HCl Buccal Film ... enough to require daily, around-the-clock, long-term opioid treatment and ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... 2011 Kensey Nash Corporation (Nasdaq: KNSY ) ... (SBIR) grant from the National Institutes of Health (NIH). ... $1.9 million Phase II SBIR grant to further investigate the ... repair procedures.  The Company will develop and evaluate the ability ...
... Nov. 7, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Inc. (NYSE ... specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine ... announced that the earnings conference call for the first ... will be held at 8:30 a.m. Eastern Time on ...
Cached Medicine Technology:TPI to Host First Quarter Fiscal Year 2012 Earnings Conference Call on Monday, November 14, 2011 at 8:30 a.m. ET 2
(Date:12/25/2014)... 2014 The report “TS-1 (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... an anti-cancer drug which is typically used for treating ... used for treating gastric cancer and pancreatic cancer. TS-1 ... drug was first approved in 1999 in Japan for ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping ... of the models at LunaDress.co.uk come with big discounts, up to ... veil can turn out to be a most exciting memory and ... always bring surprise to a wedding. On the updated fashion blog, ... veils for a big day . , Going out with friends ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... North Carolina (PRWEB) December 25, 2014 ... North Carolina Retirement Community, recently showed their generous ... girls of the Catawba County Parenting Network- Grandparents ... the 10 children gathered around the largest Christmas ... to open presents purchased by residents of the ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2
... Thousands of research studies have documented how the ... the cardiovascular system, particularly among people diagnosed with ... on this topic creates difficulty for many physicians ... recommendations related to these oils. In the March ...
... Intracranial hypertension left patients almost 5 times more likely ... News) -- Black Americans are more likely than other ... intracranial hypertension, or increased pressure in the brain, according ... School of Medicine in Atlanta reviewed the medical records ...
... a rare type of ovarian cancer, is less sensitive ... more common high-grade ovarian cancers, according to researchers from ... The findings were reported at the Society of Gynecologic ... retrospective study is the first to analyze how women ...
... March 10 Give an Hour, (http://www.giveanhour.org ), ... to returning Veterans and their loved ones,announces that ... network., In an effort to supplement the ... the military health care system, Give an Hour,s,services ...
... about climate change, energy security, and other concerns expressed ... USA launched From Electrons to Elections, a science and ... From Electrons to Elections is a non-partisan resource designed ... issues and provide them with the platforms of the ...
... be getting them, study says , , MONDAY, March 10 (HealthDay ... choices for kidney cancer more than clinical factors such as ... finds. , This means many patients who are candidates ... where only part of the kidney is removed, may not ...
Cached Medicine News:Health News:Mayo Clinic proceedings highlights research about cardiovascular benefits of omega-3 fatty acids 2Health News:Brain Disease Causes More Vision Loss in Blacks 2Health News:Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers 2Health News:Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers 3Health News:1,000 Mental Health Professionals Join National Network to Provide Free Counseling to Returning Veterans and their Families 2Health News:Student Pugwash USA launches science policy election guide for young voters 2Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 2Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 3
Instrument Cover for Vibratome....
This is a perfect tool for retrieving free floating sections from the Vibratome bath....
Vibratome Specimen Adhesive is a special formulation developed by a major adhesive manufacturer for applications such as tissue mounting. The advantage of this adhesive is that it has a strong holdi...
Specimen mounts are designed to allow for the rotation of the specimen in the Vibratome vice assembly for sectioning at different horizontal orientations....
Medicine Products: